In the United States, more than 5 million people currently have Alzheimer's disease, and a new case develops every 66 seconds. 1 The annual number of new cases of Alzheimer's and other dementias is projected to double by 2050, representing a critical burden for the world's healthcare systems. 1 
The role of tau tangles
Several theories exist to explain the cause of Alzheimer's disease, and three features of Alzheimer's have attracted the most attention: disturbed cholinergic function, the amyloid cascade, and tau pathologies.
Disruptions in the cholinergic and glutamatergic neurotransmitters formed the basis for the development of current approved treatments for Alzheimer's disease. These treatments, however, are essentially symptomatic and provide only modest and temporary improvements in cognition and global functioning.
The discovery of mutations in the amyloid precursor protein (APP) gene led to the amyloid cascade hypothesis. 4 In this hypothesis, mutations in APP have been considered to cause a build-up of extracellular amyloid-ß in the brain. 5 However, while detection of this build-up may be useful for diagnostic purposes, antiamyloid therapeutic agents have shown disappointing results in clinical trials. 6, 7 Attention has more recently been focused on the hypothesis that formation of "tau tangles" (more formally described as neurofibrillary tangles formed of paired helical filaments of tau protein sub-units that form inside neurons) leads to neurodegeneration. 8, 9 This pathology begins to develop up to 20 years before clinical symptoms appear. 10 Unlike other hypotheses, the tau mechanism shows a correlation between clinical symptoms and tau pathology. The reduction in the presence of "tau tangles" in the brain is thus a potential focus for therapeutic product development in Alzheimer's disease. 10 TauRx Co-founder and Chairman, Professor Claude Wischik, first found that the tangles linked with Alzheimer's are made of sub-units of tau protein more than 30 years ago. Professor Wischik and his colleagues estimate that about 50% of the U.S. population over age 45 have some form of tau pathology in their brains. 10 This forecast reinforces the importance of developing new treatments to halt and prevent tau tangles from forming and spreading throughout the brain.
